Patents by Inventor Tania Crombet Ramos

Tania Crombet Ramos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240279348
    Abstract: The present invention relates to the fields of biotechnology and medicine and provides the use of monoclonal antibodies against the epidermal growth factor receptor in the treatment of diseases of infectious origin that leading to a hypoxemic acute respiratory failure.
    Type: Application
    Filed: June 6, 2022
    Publication date: August 22, 2024
    Inventors: Tania CROMBET RAMOS, Mayra RAMOS SUZARTE, Danay SAAVEDRA HERNÁNDEZ, Ana Laura AÑÉ KOURÍ, Rolando PÉREZ RODRÍGUEZ, Henrry DÍAZ LONDRES, Jorge JIMÉNEZ ARMADA, Kalet LEÓN MONZÓN, Anselmo Antonio ABDO CUZA
  • Publication number: 20240173392
    Abstract: The present invention relates to the branches of Biotechnology and Medicine. It describes the use of therapeutic compositions comprising a compound that blocks epidermal growth factor and an antibody that blocks the PD-1/PD-1 ligand signaling pathway in the treatment of tumors of epithelial origin, particularly those that express the native form for human KRAS protein. In patients with cancer of epithelial origin expressing native KRAS treated with said therapeutic compositions, an increase in their survival was observed.
    Type: Application
    Filed: May 19, 2022
    Publication date: May 30, 2024
    Inventors: Tania Crombet Ramos, Circe Mesa Pardillo, Kalet León Monzón, Zaima Mazorra Herrera, Danay Saavedra Hernández, Patricia Lorenzo Luaces Álvarez, Grace Dy, Mary Reid, Rachel Evans, Jason Muhitch, Kelvin Lee, Alan Hutson, Candace Johnson
  • Publication number: 20230256069
    Abstract: The present invention is related to the fields of Biotechnology and Medicine. Particularly, it describes the use of epidermal growth factor (EGF) deprivation agents that contribute to lowering and/or depleting serum epidermal growth factor levels, which has implications in the treatment of the chronic obstructive pulmonary disease. These agents can be vaccine compositions comprising as active principle the conjugate between recombinant human EGF and a carrier protein.
    Type: Application
    Filed: July 19, 2021
    Publication date: August 17, 2023
    Inventors: Amparo Emilia Macias Abraham, Tania Crombet Ramos, Kalet León Monzón, Danay Saavedra Hernández, Orestes Santos Morales, Elia Neninger Vinageras, Pedro Pablo Pino Alfonso, Jenysbel de la Caridad Hernandez Reyes, Mary Reid, Kelvin Lee
  • Publication number: 20230151107
    Abstract: The present invention provides the use of anti-CD6 antibodies that specifically bind to domain 1 of CD6 for treating effects of a coronavirus or bacterial agent and particularly COVID-19 and variants thereof. The anti-CD6 antibodies of the present invention exhibit therapeutic activity by reducing the overactive immune response, such as the high expression levels of cytokines.
    Type: Application
    Filed: March 3, 2021
    Publication date: May 18, 2023
    Inventors: Pradip NAIR, Jose Enrique Montero CASIMIRO, Kiran MAZUMDARSHAW, Usha BUGHANI, Sandeep Nilkanth ATHALYE, Melarkode Subbaraman RAMAKRISHNAN, Tania CROMBET RAMOS, Kalet LEÓN MONZÓN, Mayra RAMOS SUZARTE
  • Patent number: 8841251
    Abstract: A vaccine composition for therapeutic use thereof on cancer patients includes a chemical conjugate of human recombining Epidermic Growth Factor (hrEGF) and a combining protein P64k for performing a conjugation reaction which produces said chemical conjugate in a controlled and reproducible manner. The preferred conjugate surprisingly increases the immunogenic activity causing significant increases in the anti-EGF antibody titers in humans, and provides a vaccine preparation with more than one type of effective dose presentation which enables the immunization dose per patient to be increased, but without involving an increase in immunization frequency and/or the number of immunization sites.
    Type: Grant
    Filed: January 10, 2012
    Date of Patent: September 23, 2014
    Assignee: Centro de Immunologia Molecular (CIM)
    Inventors: Gryssell Rodriguez Martinez, Lisel Vina Rodriguez, Loany Calvo Gonzalez, Ariadna Cuevas Fiallo, Ernesto Chico Veliz, Agustin Bienvenido Lage Davila, Tania Crombet Ramos, Arama Albisa Novo, Gisela Maria Gonzalez Marinello
  • Patent number: 8778879
    Abstract: The present invention concerns the biotechnology sector and more specifically human healthcare. In particular, the present invention describes a vaccine composition for therapeutic use thereof on cancer patients. The vaccine composition described in the present invention has as active principle a chemical conjugate of human recombining Epidermic Growth Factor (hrEGF) and are combining protein P64k. In addition, specific conditions are described for performing a conjugation reaction which produces said chemical conjugate in a controlled and reproducible manner. In another embodiment, the present invention concerns a method for purification of the chemical conjugate which not only provides greater purity for the therapeutic composition, but surprisingly increases the immunogenic activity causing significant increases in the anti-EGF antibody titers in humans.
    Type: Grant
    Filed: June 26, 2008
    Date of Patent: July 15, 2014
    Assignee: Centro de Inmunologia Molecular (CIM)
    Inventors: Gryssell María Rodríguez Martínez, Lisel Viña Rodríguez, Loany Calvo González, Ariadna Cuevas Fiallo, Ernesto Chico Véliz, Agustín Bienvenido Lage Dávila, Tania Crombet Ramos, Airama Albisa Novo, Gisela Maria González Marinello
  • Publication number: 20130039940
    Abstract: A vaccine composition for therapeutic use thereof on cancer patients includes a chemical conjugate of human recombining Epidermic Growth Factor (hrEGF) and a combining protein P64k for performing a conjugation reaction which produces said chemical conjugate in a controlled and reproducible manner. The preferred conjugate surprisingly increases the immunogenic activity causing significant increases in the anti-EGF antibody titers in humans, and provides a vaccine preparation with more than one type of effective dose presentation which enables the immunization dose per patient to be increased, but without involving an increase in immunization frequency and/or the number of immunization sites.
    Type: Application
    Filed: January 10, 2012
    Publication date: February 14, 2013
    Inventors: Gryssell Rodriguez Martinez, Lisel Vina Rodriguez, Loany Calvo Gonzalez, Ariadna Cuevas Fiallo, Ernesto Chico Veliz, Agustin Bienvenido Lage Davila, Tania Crombet Ramos, Arama Albisa Novo, Gisela Maria Gonzalez Marinello
  • Publication number: 20100196412
    Abstract: The present invention relates to the biotechnological field and particularly to the human health. More particularly, the present invention relates to a vaccine composition for therapeutic use in cancer patients. The vaccine composition of the present invention has as active principle a chemical conjugated between the human recombinant Epidermal Growth Factor (hrEGF) and the P64K recombinant protein. In another embodiment, the present invention relates to the conjugation procedure to obtain, a chemical conjugated under controlled and reproducible parameters. In a preferred embodiment, the present invention relates to the procedure for purifying the chemical conjugated with a higher purity of the therapeutical vaccine composition, and a surprisingly increased immunogenic activity, inducing a significant increase of the anti-EGF antibody titers in humans.
    Type: Application
    Filed: June 26, 2008
    Publication date: August 5, 2010
    Applicant: CENTRO DE INMUNOLOGIA MOLECULAR
    Inventors: Gryssell Maria Rodriguez Martinez, Bisel Viña Rodriguez, Loany Galvo González, Ariadna Cuevas Fiallo, Ernesto Chico Véliz, Agustin Bienvenido Lage Dávila, Tania Crombet Ramos, Airama Albisa Novo, Gisela Mar González Marinello